Biotech
-
Engrail’s precision psychiatry drugs get more buy in from venture investors
The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.
By Jacob Bell • March 19, 2024 -
Bluebird, short on cash, takes on $175M in debt financing
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
By Delilah Alvarado • March 18, 2024 -
Trendline
Top 5 stories from BioPharma Dive
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By BioPharma Dive staff -
Sponsored by Veeva
Give HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
Sponsored by Cardinal Health Sonexus™ Access and Patient Support
The digital divide: Balancing automation and human interaction regardless of the patient support program model
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
March 18, 2024 -
Contineum, a startup born from a Roche buyout, files for IPO
The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.
By Ben Fidler • March 17, 2024 -
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
By Ben Fidler • March 15, 2024 -
German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing
The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.
By Gwendolyn Wu • March 14, 2024 -
Emerging biotech
IFM, an unorthodox biotech startup, scores third buyout with Novartis deal
With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million upfront and the potential for billions more in future payments.
By Kristin Jensen • March 13, 2024 -
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
By Ben Fidler • March 12, 2024 -
ALS drug development
After surprise trial failure, ALS doctors brace for one less treatment option
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
By Jacob Bell • March 12, 2024 -
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
By Delilah Alvarado • March 11, 2024 -
Q&A
Amylyx CEOs look for a path forward following major setback
Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.
By Jacob Bell • March 11, 2024 -
Biotech stock fundings headed for best quarter in 3 years, Jefferies says
Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said.
By Ben Fidler • March 11, 2024 -
Sponsored by PurpleLab
Can using SDoH data help identify patient populations who could benefit from weight loss drugs?
SDoH data can help companies understand the footprint of weight loss medications in the market and their impact across populations.
March 11, 2024 -
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO
The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.
By Gwendolyn Wu • March 7, 2024 -
European VC Invivo readies its latest fund to back new biotechs
The Barcelona-based firm, which is targeting about 100 million euros for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.
By Gwendolyn Wu • March 6, 2024 -
Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work
The startup, one of a number of young biotechs coming after Bristol Myers’ Sotyktu, will use the cash to fund a late-stage trial in plaque psoriasis.
By Delilah Alvarado • March 6, 2024 -
Emerging biotech
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.
By Gwendolyn Wu • March 6, 2024 -
Emerging biotech
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead.
By Gwendolyn Wu , Ben Fidler • March 5, 2024 -
Nocion, chasing GSK, pulls in $62M for chronic cough drug
Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.
By Gwendolyn Wu • March 4, 2024 -
Bayer pays $310M to buy into BridgeBio heart drug
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
By Ben Fidler • March 4, 2024 -
Sponsored by QIAGEN
Using knowledge graphs to drive drug discovery
How are knowledge graphs changing the path of drug discovery?
March 4, 2024 -
FogPharma pulls in $145M to support cancer drug research
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
By Gwendolyn Wu • March 1, 2024 -
Gritstone to lay off 40% of workforce after costly study delay
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.
By Ben Fidler • March 1, 2024